Request your benchmark study
This independent study of more than 1,400 U.S. public companies examines their risk exposures, hedging, capital markets activity, and hedge accounting practices. Request the report to see how your debt and hedging practices compared with your peers.
- Industries most active with M&A
- How hedging practices have changed over the past three years
- The most commonly used derivative products
- Asset classes where peer organizations face the most exposure
Chatham Hedging Advisors, LLC (CHA) is a subsidiary of Chatham Financial Corp. and provides hedge advisory, accounting and execution services related to swap transactions in the United States. CHA is registered with the Commodity Futures Trading Commission (CFTC) as a commodity trading advisor and is a member of the National Futures Association (NFA); however, neither the CFTC nor the NFA have passed upon the merits of participating in any advisory services offered by CHA. For further information, please visit chathamfinancial.com/legal-notices.
Transactions in over-the-counter derivatives (or “swaps”) have significant risks, including, but not limited to, substantial risk of loss. You should consult your own business, legal, tax and accounting advisers with respect to proposed swap transaction and you should refrain from entering into any swap transaction unless you have fully understood the terms and risks of the transaction, including the extent of your potential risk of loss. This material has been prepared by a sales or trading employee or agent of Chatham Hedging Advisors and could be deemed a solicitation for entering into a derivatives transaction. This material is not a research report prepared by Chatham Hedging Advisors. If you are not an experienced user of the derivatives markets, capable of making independent trading decisions, then you should not rely solely on this communication in making trading decisions. All rights reserved.
Our featured insights
Treasuries, crypto, and oil bring us into 2021
The Georgia Senate election results were finalized during a tumultuous week, along with the official certification of Joe Biden as the next U.S. President.
An Altered Currency Landscape and Impact to Corporate Hedging Programs
This session will provide an update on FX markets, along with strategic and operational actions corporates are taking to ensure their programs keep pace with market dynamics, effectively assess and manage risk, and continue to achieve objectives.
Stock market gains mask weak economic end to 2020
While nations worldwide continue to distribute the COVID-19 vaccine, Americans have seen some progress in receiving their stimulus checks. The Treasury Department began depositing $600 checks in to Americans’ bank accounts last week, causing equity markets to rise.
Are all things merry and bright?
With less than 10 days to go before year-end, lawmakers reached a final agreement on a new coronavirus relief package expected to be around $900 billion. Market expectations are high that Congress can pass it into law this week, providing needed relief for businesses, communities, and households.
Vaccinations, stimulus talks, and Brexit lead the headlines in the final weeks of 2020
Positive vaccine news has the equities market poised for another rally as futures are pointing up heading into this week. The 10-year Treasury and 5-year swap rate are floating around 0.90% and 0.42%, respectively as the markets open this Monday.
LIBOR transition readiness checklist for corporates
This proprietary checklist is informed by Chatham Financial's team of hedging, regulatory, and accounting advisors with visibility across 100+ banks and 3,000+ clients. By taking these 12 key actions, your treasury and accounting teams can confidently prepare for the transition from LIBOR to SOFR.
Vaccine optimism fuels risk asset growth while rates remain rangebound
As of noon on November 30, global stock markets exhibited record growth during the month of November, fueled by successive vaccine announcements being queued up for emergency approval by the U.S. Government.
COVID-19 cases and restrictions weigh on economic data
The market’s focus last week continued to laser in on all things coronavirus related. While investors applauded positive vaccine news out of Moderna and Pfizer early in the week, the continued surge in cases and increasing levels of restrictions weighed down on economic data as the week progressed.